China 2014: Five Commercial Must-Reads
This article was originally published in PharmAsia News
Change, turmoil and transition have marked the passing Year of the Horse for the China pharma industry. If you missed some of the highlights, here is an opportunity to check out the top China commercial happenings in 2014.
You may also be interested in...
Pharma executives in China may soon get an earful of the name Sanming, as the populist healthcare reform model that began at the small city in Fujian is rolled out nationwide and impacts profoundly how drugs are tendered, priced and distributed.
China has signaled that it will offer a more level playing field to foreign players as part of a bid to join a major regional trade pact but some see the gesture as offering little real relief and high hurdles remain.
Despite administering a total of 2.2 billion COVID-19 shots, China as the first country to experience the coronavirus outbreak has yet to open its borders, while more effective mRNA vaccines are still nowhere to be found amid apparent delays for the licensed-in lead candidate.